LifeVantage Corporation

LifeVantage Corporation (LFVN) Market Cap

LifeVantage Corporation has a market capitalization of $63M.

Financials based on reported quarter end 2025-12-31

Price: $4.92

β–Ό -0.21 (-4.09%)

Market Cap: 63.00M

NASDAQ Β· time unavailable

CEO: Steven R. Fife

Sector: Consumer Defensive

Industry: Packaged Foods

IPO Date: 1994-04-07

Website: https://www.lifevantage.com

LifeVantage Corporation (LFVN) - Company Information

Market Cap: 63.00M Β· Sector: Consumer Defensive

LifeVantage Corporation engages in the identification, research, development, formulation, sale, and distribution of nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care products, bath and body, and targeted relief products. The company offers Protandim, a line of scientifically validated dietary supplements; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support digestive system health; a line of weight management products under the PhysIQ brand; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a line of energy drink mixes. It also provides anti-aging skin care products, including facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, the company offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website, as well as through a network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and China. LifeVantage Corporation is headquartered in Lehi, Utah.

Analyst Sentiment

67%
Buy

Based on 2 ratings

Analyst 1Y Forecast: $7.33

Average target (based on 2 sources)

Consensus Price Target

Low

$5

Median

$5

High

$5

Average

$5

Potential Upside: 1.6%

Price & Moving Averages

Loading chart...

Fundamentals Overview

Loading fundamentals overview...

πŸ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"LFVN reported revenue of $48.9M and a net income of $276k for the fiscal year ending December 31, 2025. The company generated an operating cash flow of $2.79M with free cash flow at $1.71M, indicating a positive cash generation relative to its expenditures. The balance sheet reflects total assets of $61.17M and total liabilities of $28.18M, resulting in equity of $32.99M and a modest net debt of $510k. Despite these strengths, LFVN has experienced significant market challenges, reflected by a 1-year price decline of 72.17% and a negative YTD change of 28.19%. Furthermore, while the company pays consistent dividends at $0.045 per share, the drastic price decrease positions the current yield unfavorably. The lack of buybacks or significant price appreciation diminishes the overall shareholder returns in this environment. Analyst consensus points to a price target of $5, which suggests potential upside from the current price of $4.33, although current market sentiment remains cautious."

Revenue Growth

Neutral

Revenue of $48.9M shows reasonable growth prospects.

Profitability

Neutral

Net income of $276k, indicating limited profitability.

Cash Flow Quality

Positive

Positive free cash flow of $1.71M reflects good cash management.

Leverage & Balance Sheet

Neutral

Solid balance sheet with low net debt, though liabilities are significant.

Shareholder Returns

Neutral

Significant price decline overshadowing dividend payouts.

Analyst Sentiment & Valuation

Fair

Analyst price target suggests undervaluation but sentiment remains negative.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

So What?: Q2 results were dominated by MINDBODY GLP-1 disruptionβ€”revenue fell 27.8% YoY to $48.9M, with MINDBODY sales down $16.2M. Management responded with concrete levers: a conservative $2.4M MINDBODY inventory reserve and ongoing pricing/engagement tactics (20% off through Feb, Activate Ninety trainer events, app tracking feature, and win-back campaigns). They argue the category is still winnable via natural science/positioning, but the competitive reality is that pharma GLP-1 is now cheaper, insured, and available in pillsβ€”shrinking the value gap versus MINDBODY. The silver lining is LoveBiome: $4.1M revenue contribution and early product traction (Axila X and Phytopower B; just under 1,000 participants on kickoff calls) with additional launches planned. Analyst pressure focused on cash dynamics and MINDBODY demand trajectory; management acknowledged churn in customer/consultant momentum and did not provide a precise rebound inflection, only stating trends β€œstabilized” and Q4 should be a higher revenue mix than Q3.

AI IconGrowth Catalysts

  • LoveBiome integration momentum; two LoveBiome product launches earlier in the week (Axila X and Phytopower B) with just under 1,000 kickoff call participants
  • Upcoming LoveBiome launches in the next couple of months to further round out the portfolio
  • HealthyEdge stack positioning (Protandim NRS2 synergizer + P84) as a lead enrollment story
  • P84 (patent-pending) continued strong adoption in the gut microbiome market; in vitro testing validation referenced from October Momentum event

Business Development

  • MINDBODY GO-to-market promotions and loyalty/win-back efforts (20% off sale carried through January into February; Activate Ninety trainer call series in December)
  • Shopify partnership (pilot program on track) to modernize e-commerce and improve conversions/customer experience
  • LoveBiome acquisition integration (transaction closed; pilots/systems integrated)

AI IconFinancial Highlights

  • Reported net revenue: $48.9M, down 27.8% YoY from $67.8M; up 2.9% sequentially
  • MINDBODY GLP-1 sales declined $16.2M YoY (primary driver of revenue decline)
  • LoveBiome contributed $4.1M in quarter revenue (product sales only disclosed as ~$4M; other consultant-driven revenue not broken out)
  • Gross profit percentage: 74% vs 80.5% prior year; down 650 bps, driven by one-time $2.4M inventory obsolescence allowance (MINDBODY) plus higher shipping/warehouse expenses
  • Excluding the $2.4M inventory reserve: non-GAAP gross profit percentage 78.8%
  • Commissions & incentive expense as % of revenue: 40.7% vs 48.0% prior year
  • SG&A: $15.8M or 32.3% of revenue vs $18.6M or 27.5% prior year (increase due to lower sales volume and elevated event-related expenses)
  • GAAP operating income: $0.5M vs $3.4M prior year; adjusted non-GAAP operating income: $2.6M vs $3.9M prior year
  • GAAP net income: $0.3M or $0.02 diluted EPS vs $2.6M or $0.19 prior year
  • Adjusted non-GAAP net income: $1.9M or $0.15 diluted EPS vs $3.0M or $0.22 prior year
  • Adjusted EBITDA: $3.9M (7.9% of revenue) vs $6.5M (9.6% of revenue) prior year
  • Balance sheet: $10.2M cash, no debt at end of Q2
  • No explicit tax/tariff mention in transcript

AI IconCapital Funding

  • Cash used for LoveBiome transaction closing: $3.7M (second quarter)
  • Cash from operations: $0.5M during first six months of fiscal 2026 vs $8.6M in same period prior year
  • Capital expenditures: $1.5M first six months fiscal 2026 vs $0.8M prior year (technology infrastructure investment)
  • Share repurchases: none in Q2; $0.6M repurchased 44,000 shares during first six months
  • New $60M share repurchase authorization approved; replaces prior program; repurchases permitted through 12/31/2027 (open market and private transactions)
  • Quarterly cash dividend declared: $0.45/share; payable 03/16/2026; record date 03/02/2026

AI IconStrategy & Ops

  • MINDBODY competitive response: 20% product discount promo carried through January into February; December Activate Ninety weekly trainer-call event with recorded distribution; January app feature added for customer/consultant calorie/activity tracking, reminders, and goal setting; active win-back campaigns targeting prior MINDBODY users
  • Inventory reserve: conservative reserve against portion of MINDBODY inventory due to market right-sizing/visibility changes after supply ramp; shelf life referenced as two years
  • Shipping/warehouse cost pressures contributed to gross margin compression
  • GLP-1 inventory reserve described as a conservative risk-management action after being 'ahead of ourselves' on supply chain ramp post-launch
  • Shopify modernization: pilot program on track with expected improved conversion rates and customer experience; also planned back-office/consultant tool enhancements to align with Shopify rollout

AI IconMarket Outlook

  • FY 2026 guidance (unchanged in transcript but explicitly reiterated): revenue $185M to $200M; adjusted EBITDA $15M to $19M; adjusted EPS $0.60 to $0.80 (fully diluted)
  • Q3/Q4 revenue mix commentary: expects MINDBODY trends stabilized; build from Q3 into Q4; Q4 likely higher proportion of revenue than Q3
  • Expectation of continued LoveBiome rollout engagement in back half of year to support Q3β†’Q4 improvement

AI IconRisks & Headwinds

  • Natural GLP-1 market competition intensified post MINDBODY launch due to pharmaceutical GLP-1 drugs becoming more accessible/affordable, wider insurance coverage, and new formats including pills
  • MINDBODY promotional necessity and demand normalization: management states the company got ahead of itself on inventory during early months after a fast sell-out (sold out initial stock within ~3 weeks)
  • Candid performance issue: management acknowledges Q2 did not meet expectations; GLP-1 market shift drove revenue decline
  • Consultant/customer momentum issues: decline in customer base and modest decline in consultant base; consultants had centered on MINDBODY as the enrollment story, reducing momentum in other hero products; NRF2 collagen slowdown cited as part of the shift
  • Operational financial pressure: gross margin hit by one-time inventory obsolescence reserve ($2.4M) and higher shipping/warehouse expenses
  • No tariff/macro mitigation steps mentioned in transcript

Sentiment: CAUTIOUS

Note: This summary was synthesized by AI from the LFVN Q2 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
πŸ“

SEC Filings (LFVN)

Β© 2026 Stock Market Info β€” LifeVantage Corporation (LFVN) Financial Profile